美西律在肾功能不全患者中的药代动力学。
Pharmacokinetics of mexiletine in renal insufficiency.
作者信息
El Allaf D, Henrard L, Crochelet L, Delapierre D, Carlier J, Dresse A
出版信息
Br J Clin Pharmacol. 1982 Sep;14(3):431-5. doi: 10.1111/j.1365-2125.1982.tb02003.x.
Abstract
1 The aim of this study was to evaluate the influence of renal insufficiency on the plasma pharmacokinetics of mexiletine, a new antiarrhythmic agent, in human beings. 2 Mexiletine was administered orally three times daily for 10 days to 15 patients with chronic renal failure (creatinine clearance lower than 30 ml/min) and to 9 subjects with normal renal function. 3 The use of low doses of mexiletine was possible owing to the development of a new fluorescence h.p.l.c. method with a limit of sensitivity lower than 20 gn/ml. 4 Our results clearly indicate that the plasma kinetics of mexiletine are not modified when the renal clearance of creatinine is higher than 10 ml/min.
摘要
- 本研究的目的是评估肾功能不全对新型抗心律失常药物美西律在人体血浆药代动力学的影响。2. 对15例慢性肾功能衰竭（肌酐清除率低于30 ml/min）患者和9例肾功能正常的受试者，每日口服美西律3次，共10天。3. 由于开发了一种灵敏度极限低于20 ng/ml的新型荧光高效液相色谱法，才得以使用低剂量的美西律。4. 我们的结果清楚地表明，当肌酐肾清除率高于10 ml/min时，美西律的血浆动力学未发生改变。
相似文献
1
Pharmacokinetics of mexiletine in renal insufficiency.美西律在肾功能不全患者中的药代动力学。
Br J Clin Pharmacol. 1982 Sep;14(3):431-5. doi: 10.1111/j.1365-2125.1982.tb02003.x.
2
Pharmacokinetics of mexiletine in renal insufficiency.
Acta Cardiol Suppl. 1980(25):55-65.
3
Pharmacokinetics and nondialyzability of mexiletine in renal failure.
Clin Pharmacol Ther. 1985 Jun;37(6):649-53. doi: 10.1038/clpt.1985.105.
4
Effect of rifampicin treatment on the kinetics of mexiletine.利福平治疗对美西律动力学的影响。
Eur J Clin Pharmacol. 1982;23(3):261-6. doi: 10.1007/BF00547565.
5
Pharmacokinetics of intravenous mexiletine in patients with acute myocardial infarction.急性心肌梗死患者静脉注射美西律的药代动力学
J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):1-6.
6
Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction.急性心肌梗死患者口服美西律的药代动力学
Eur J Clin Pharmacol. 1983;25(6):773-7. doi: 10.1007/BF00542518.
7
Stereoselective disposition of mexiletine in man.美西律在人体中的立体选择性分布。
Br J Clin Pharmacol. 1986 May;21(5):481-7. doi: 10.1111/j.1365-2125.1986.tb02829.x.
8
Effects of age on the pharmacokinetics of mexiletine.年龄对美西律药代动力学的影响。
Int J Clin Pharmacol Res. 1986;6(4):303-7.
9
Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.美西律的处置：对尿液酸化和碱化反应的个体差异。
Br J Clin Pharmacol. 1983 Sep;16(3):281-4. doi: 10.1111/j.1365-2125.1983.tb02162.x.
10
[Pharmacokinetic studies with mexiletine in patients with renal insufficiency].
Adv Clin Pharmacol. 1978;16:17-27.
引用本文的文献
1
Clinical pharmacokinetics of mexiletine.美西律的临床药代动力学。
Clin Pharmacokinet. 1999 Nov;37(5):361-84. doi: 10.2165/00003088-199937050-00002.
2
Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.美西律。其在疼痛性糖尿病神经病变中治疗应用的综述。
Drugs. 1998 Oct;56(4):691-707. doi: 10.2165/00003495-199856040-00016.
3
Adverse effects of class I antiarrhythmic drugs.I类抗心律失常药物的不良反应。
Drug Saf. 1997 Jul;17(1):8-36. doi: 10.2165/00002018-199717010-00002.
4
Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.美西律的处置：对尿液酸化和碱化反应的个体差异。
Br J Clin Pharmacol. 1983 Sep;16(3):281-4. doi: 10.1111/j.1365-2125.1983.tb02162.x.
5
Clinical pharmacokinetics of the newer antiarrhythmic agents.新型抗心律失常药物的临床药代动力学
Clin Pharmacokinet. 1984 Sep-Oct;9(5):375-403. doi: 10.2165/00003088-198409050-00001.
6
Mexiletine clearance during peritoneal dialysis.腹膜透析期间美西律的清除率。
Br J Clin Pharmacol. 1985 Jun;19(6):857-8. doi: 10.1111/j.1365-2125.1985.tb02732.x.
7
Cirrhosis of the liver markedly impairs the elimination of mexiletine.肝硬化会显著损害美西律的消除。
Eur J Clin Pharmacol. 1986;30(1):83-8. doi: 10.1007/BF00614201.
8
[Mexiletine in terminal renal failure and various dialysis procedures].
Klin Wochenschr. 1989 Oct 2;67(19):995-8. doi: 10.1007/BF01716063.
9
[Treatment with mexiletine. Clinical and pharmacokinetic studies].[美西律治疗。临床及药代动力学研究]
Klin Wochenschr. 1988 Jun 1;66(11):475-81. doi: 10.1007/BF01876168.
10
Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.运用药代动力学原理对抗心律失常药物治疗进行实际优化。
Clin Pharmacokinet. 1991 Feb;20(2):151-66. doi: 10.2165/00003088-199120020-00006.
本文引用的文献
1
Pharmacokinetics of mexiletine in renal insufficiency.
Acta Cardiol Suppl. 1980(25):55-65.
2
Mexiletine in the treatment of ventricular arrhythmias.美西律治疗室性心律失常
Acta Cardiol Suppl. 1980(25):127-35.
3
Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range.荧光胺：一种用于测定皮摩尔范围内氨基酸、肽、蛋白质和伯胺的试剂。
Science. 1972 Nov 24;178(4063):871-2. doi: 10.1126/science.178.4063.871.
4
Mexiletine (Kö 1173) in the management of ventricular dysrhythmias.美西律（Kö 1173）用于室性心律失常的治疗。
Lancet. 1973 Aug 25;2(7826):404-7. doi: 10.1016/s0140-6736(73)92271-x.
5
Treatment of ventricular arrhythmias with mexiletine (Kö 1173).美西律（Kö 1173）治疗室性心律失常
Lancet. 1973 Aug 25;2(7826):399-404. doi: 10.1016/s0140-6736(73)92270-8.
6
Absorption, distribution and elimination of mexiletine.
Postgrad Med J. 1977;53 Suppl 1:50-5.
7
Mexiletine in normal volunteers.美西律在正常志愿者中的应用。
Br J Clin Pharmacol. 1978 Oct;6(4):372-3. doi: 10.1111/j.1365-2125.1978.tb00868.x.
8
[Pharmacokinetic studies with mexiletine in patients with renal insufficiency].
Adv Clin Pharmacol. 1978;16:17-27.
9
The clinical pharmacology of mexiletine.美西律的临床药理学。
Br J Clin Pharmacol. 1978 Aug;6(2):103-8. doi: 10.1111/j.1365-2125.1978.tb00833.x.
10
Long term treatment of ventricular arrhythmias with oral mexiletine.
Postgrad Med J. 1977;53 Suppl 1:146-9.
Zotero 插件